Amedeo Smart

Free Medical Literature Service

 

Amedeo

Influenza
  Free Subscription

Articles published in
J Exp Med
    June 2024
  1. WU TT, Travaglini KJ, Rustagi A, Xu D, et al
    Interstitial macrophages are a focus of viral takeover and inflammation in COVID-19 initiation in human lung.
    J Exp Med. 2024;221:e20232192.
    >> Share

    February 2024
  2. BASTARD P, Gervais A, Taniguchi M, Saare L, et al
    Higher COVID-19 pneumonia risk associated with anti-IFN-alpha than with anti-IFN-omega auto-Abs in children.
    J Exp Med. 2024;221:e20231353.
    >> Share

    November 2023
  3. RUTERBUSCH MJ, Hondowicz BD, Takehara KK, Pruner KB, et al
    Allergen exposure functionally alters influenza-specific CD4+ Th1 memory cells in the lung.
    J Exp Med. 2023;220:e20230112.
    >> Share

    September 2023
  4. WANG Z, Muecksch F, Raspe R, Johannsen F, et al
    Memory B cell development elicited by mRNA booster vaccinations in the elderly.
    J Exp Med. 2023;220:e20230668.
    >> Share

    August 2023
  5. RYBKINA K, Bell JN, Bradley MC, Wohlbold T, et al
    SARS-CoV-2 infection and recovery in children: Distinct T cell responses in MIS-C compared to COVID-19.
    J Exp Med. 2023;220:e20221518.
    >> Share

  6. LIN YS, Chang YC, Chao TL, Tsai YM, et al
    The Src-ZNRF1 axis controls TLR3 trafficking and interferon responses to limit lung barrier damage.
    J Exp Med. 2023;220:e20220727.
    >> Share

  7. GILBERTSON B, Subbarao K
    Mammalian infections with highly pathogenic avian influenza viruses renew concerns of pandemic potential.
    J Exp Med. 2023;220:e20230447.
    >> Share

    May 2023
  8. GARCIA-GARCIA A, Perez de Diego R, Flores C, Rinchai D, et al
    Humans with inherited MyD88 and IRAK-4 deficiencies are predisposed to hypoxemic COVID-19 pneumonia.
    J Exp Med. 2023;220:e20220170.
    >> Share

    March 2023
  9. KAISER KA, Loffredo LF, Santos-Alexis KL, Ringham OR, et al
    Regulation of the alveolar regenerative niche by amphiregulin-producing regulatory T cells.
    J Exp Med. 2023;220:e20221462.
    >> Share

    February 2023
  10. ONNIS A, Andreano E, Cassioli C, Finetti F, et al
    SARS-CoV-2 Spike protein suppresses CTL-mediated killing by inhibiting immune synapse assembly.
    J Exp Med. 2023;220.
    >> Share

  11. INOUE T, Shinnakasu R, Kawai C, Yamamoto H, et al
    Antibody feedback contributes to facilitating the development of Omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccinees.
    J Exp Med. 2023;220:e20221786.
    >> Share

    January 2023
  12. SOKAL A, Bastard P, Chappert P, Barba-Spaeth G, et al
    Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination.
    J Exp Med. 2023;220.
    >> Share

    December 2022
  13. BEER J, Crotta S, Breithaupt A, Ohnemus A, et al
    Impaired immune response drives age-dependent severity of COVID-19.
    J Exp Med. 2022;219.
    >> Share

  14. WANG Z, Zhou P, Muecksch F, Cho A, et al
    Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans.
    J Exp Med. 2022;219.
    >> Share

    November 2022
  15. SHEMESH A, Su Y, Calabrese DR, Chen D, et al
    Diminished cell proliferation promotes natural killer cell adaptive-like phenotype by limiting FcepsilonRIgamma expression.
    J Exp Med. 2022;219.
    >> Share

  16. ZHANG Q, Pizzorno A, Miorin L, Bastard P, et al
    Autoantibodies against type I IFNs in patients with critical influenza pneumonia.
    J Exp Med. 2022;219.
    >> Share

    October 2022
  17. LIM JME, Tan AT, Le Bert N, Hang SK, et al
    SARS-CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8+ and CD4+ T cells of broad specificity.
    J Exp Med. 2022;219.
    >> Share

  18. WANG Z, Muecksch F, Muenn F, Cho A, et al
    Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens.
    J Exp Med. 2022;219.
    >> Share

    September 2022
  19. AGUDELO M, Muecksch F, Schaefer-Babajew D, Cho A, et al
    Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants.
    J Exp Med. 2022;219.
    >> Share

  20. HALE M, Netland J, Chen Y, Thouvenel CD, et al
    IgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2.
    J Exp Med. 2022;219.
    >> Share

    August 2022
  21. ZHANG Q, Matuozzo D, Le Pen J, Lee D, et al
    Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia.
    J Exp Med. 2022;219.
    >> Share

  22. CHO A, Muecksch F, Wang Z, Ben Tanfous T, et al
    Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans.
    J Exp Med. 2022;219.
    >> Share

    July 2022
  23. WARE CF, Croft M, Neil GA
    Realigning the LIGHT signaling network to control dysregulated inflammation.
    J Exp Med. 2022;219.
    >> Share

  24. CAMPBELL TM, Liu Z, Zhang Q, Moncada-Velez M, et al
    Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency.
    J Exp Med. 2022;219.
    >> Share

  25. PLANCHAIS C, Fernandez I, Bruel T, de Melo GD, et al
    Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.
    J Exp Med. 2022;219.
    >> Share

    June 2022
  26. DUNCAN CJA, Skouboe MK, Howarth S, Hollensen AK, et al
    Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic.
    J Exp Med. 2022;219.
    >> Share

  27. CASTLEMAN MJ, Stumpf MM, Therrien NR, Smith MJ, et al
    SARS-CoV-2 infection relaxes peripheral B cell tolerance.
    J Exp Med. 2022;219.
    >> Share

  28. MEYTS I
    Null IFNAR1 and IFNAR2 alleles are surprisingly common in the Pacific and Arctic.
    J Exp Med. 2022;219.
    >> Share

    April 2022
  29. PUEL A, Bastard P, Bustamante J, Casanova JL, et al
    Human autoantibodies underlying infectious diseases.
    J Exp Med. 2022;219.
    >> Share

    February 2022
  30. ZHANG B, Zhang Y, Xiong L, Li Y, et al
    CD127 imprints functional heterogeneity to diversify monocyte responses in inflammatory diseases.
    J Exp Med. 2022;219.
    >> Share

  31. HOSTE L, Roels L, Naesens L, Bosteels V, et al
    TIM3+ TRBV11-2 T cells and IFNgamma signature in patrolling monocytes and CD16+ NK cells delineate MIS-C.
    J Exp Med. 2022;219.
    >> Share

  32. HILLIGAN KL, Namasivayam S, Clancy CS, O'Mard D, et al
    Intravenous administration of BCG protects mice against lethal SARS-CoV-2 challenge.
    J Exp Med. 2022;219.
    >> Share

    January 2022
  33. MAO T, Israelow B, Lucas C, Vogels CBF, et al
    A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice.
    J Exp Med. 2022;219.
    >> Share

    December 2021
  34. SHINNAKASU R, Sakakibara S, Yamamoto H, Wang PH, et al
    Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses.
    J Exp Med. 2021;218.
    >> Share

  35. LU X, Hosono Y, Nagae M, Ishizuka S, et al
    Identification of conserved SARS-CoV-2 spike epitopes that expand public cTfh clonotypes in mild COVID-19 patients.
    J Exp Med. 2021;218.
    >> Share

  36. PYLE CJ, Labeur-Iurman L, Groves HT, Puttur F, et al
    Enhanced IL-2 in early life limits the development of TFH and protective antiviral immunity.
    J Exp Med. 2021;218.
    >> Share

    November 2021
  37. RAPPE JCF, Finsterbusch K, Crotta S, Mack M, et al
    A TLR7 antagonist restricts interferon-dependent and -independent immunopathology in a mouse model of severe influenza.
    J Exp Med. 2021;218.
    >> Share

  38. FONSECA W, Malinczak CA, Fujimura K, Li D, et al
    Maternal gut microbiome regulates immunity to RSV infection in offspring.
    J Exp Med. 2021;218.
    >> Share

    October 2021
  39. DECKER T
    The early interferon catches the SARS-CoV-2.
    J Exp Med. 2021;218.
    >> Share

  40. LOPEZ J, Mommert M, Mouton W, Pizzorno A, et al
    Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs.
    J Exp Med. 2021;218.
    >> Share

    September 2021
  41. AHN M, Wang LF
    Translation from bats to humans beyond infectious diseases.
    J Exp Med. 2021;218.
    >> Share

    August 2021
  42. CHEEMARLA NR, Watkins TA, Mihaylova VT, Wang B, et al
    Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics.
    J Exp Med. 2021;218.
    >> Share

  43. WILK AJ, Lee MJ, Wei B, Parks B, et al
    Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19.
    J Exp Med. 2021;218.
    >> Share

    July 2021
  44. BASTARD P, Orlova E, Sozaeva L, Levy R, et al
    Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1.
    J Exp Med. 2021;218.
    >> Share

  45. SOLFOROSI L, Kuipers H, Jongeneelen M, Rosendahl Huber SK, et al
    Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP.
    J Exp Med. 2021;218.
    >> Share

    June 2021
  46. LANZ C, Schotsaert M, Magnus C, Karakus U, et al
    IFITM3 incorporation sensitizes influenza A virus to antibody-mediated neutralization.
    J Exp Med. 2021;218.
    >> Share

  47. SANCHO-SHIMIZU V, Brodin P, Cobat A, Biggs CM, et al
    SARS-CoV-2-related MIS-C: A key to the viral and genetic causes of Kawasaki disease?
    J Exp Med. 2021;218.
    >> Share

    May 2021
  48. ANDREANO E, Rappuoli R
    Immunodominant antibody germlines in COVID-19.
    J Exp Med. 2021;218.
    >> Share

  49. LE BERT N, Clapham HE, Tan AT, Chia WN, et al
    Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection.
    J Exp Med. 2021;218.
    >> Share

  50. MERAD M, Vabret N
    Highlights from a year in a pandemic.
    J Exp Med. 2021;218.
    >> Share

  51. BAUM A, Kyratsous CA
    SARS-CoV-2 spike therapeutic antibodies in the age of variants.
    J Exp Med. 2021;218.
    >> Share

  52. KEDL RM
    Down but far from out: The durability of SARS-CoV-2 immunity after asymptomatic infection.
    J Exp Med. 2021;218.
    >> Share

    April 2021
  53. ZHUANG Z, Lai X, Sun J, Chen Z, et al
    Mapping and role of T cell response in SARS-CoV-2-infected mice.
    J Exp Med. 2021;218.
    >> Share

  54. ONODI F, Bonnet-Madin L, Meertens L, Karpf L, et al
    SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4.
    J Exp Med. 2021;218.
    >> Share

  55. BRETON G, Mendoza P, Hagglof T, Oliveira TY, et al
    Persistent cellular immunity to SARS-CoV-2 infection.
    J Exp Med. 2021;218.
    >> Share

  56. BASTARD P, Michailidis E, Hoffmann HH, Chbihi M, et al
    Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine.
    J Exp Med. 2021;218.
    >> Share

  57. POON MML, Farber DL
    Lasting memories of SARS-CoV-2 infection.
    J Exp Med. 2021;218.
    >> Share

  58. MCCARTY NA
    Breathe-Your immune system is counting on it.
    J Exp Med. 2021;218.
    >> Share

    March 2021
  59. SCHAFER A, Muecksch F, Lorenzi JCC, Leist SR, et al
    Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo.
    J Exp Med. 2021;218.
    >> Share

  60. LU Y, Jiang R, Freyn AW, Wang J, et al
    CD4+ follicular regulatory T cells optimize the influenza virus-specific B cell response.
    J Exp Med. 2021;218.
    >> Share

  61. RODRIGUES TS, de Sa KSG, Ishimoto AY, Becerra A, et al
    Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients.
    J Exp Med. 2021;218.
    >> Share

  62. BRYANT C
    COVID-19 stokes inflammasomes.
    J Exp Med. 2021;218.
    >> Share

  63. SONG E, Zhang C, Israelow B, Lu-Culligan A, et al
    Neuroinvasion of SARS-CoV-2 in human and mouse brain.
    J Exp Med. 2021;218.
    >> Share

  64. NIMMERJAHN F, Ravetch JV
    Four keys to unlock IgG.
    J Exp Med. 2021;218.
    >> Share

    January 2021
  65. PAIK DH, Farber DL
    Influenza infection fortifies local lymph nodes to promote lung-resident heterosubtypic immunity.
    J Exp Med. 2021;218.
    >> Share

    December 2020
  66. VERAS FP, Pontelli MC, Silva CM, Toller-Kawahisa JE, et al
    SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology.
    J Exp Med. 2020;217.
    >> Share

  67. RADERMECKER C, Detrembleur N, Guiot J, Cavalier E, et al
    Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19.
    J Exp Med. 2020;217.
    >> Share

  68. MAJOR J, Wack A
    An ace model for SARS-CoV-2 infection.
    J Exp Med. 2020;217.
    >> Share

  69. KOAY HF, Fulford TS, Godfrey DI
    An unconventional view of COVID-19 T cell immunity.
    J Exp Med. 2020;217.
    >> Share

    November 2020
  70. KIM JH
    SARS-CoV-2 vaccine development, access, and equity.
    J Exp Med. 2020;217.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016